CA3247142A1 - CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY - Google Patents

CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY

Info

Publication number
CA3247142A1
CA3247142A1 CA3247142A CA3247142A CA3247142A1 CA 3247142 A1 CA3247142 A1 CA 3247142A1 CA 3247142 A CA3247142 A CA 3247142A CA 3247142 A CA3247142 A CA 3247142A CA 3247142 A1 CA3247142 A1 CA 3247142A1
Authority
CA
Canada
Prior art keywords
acid
gglu
aeea
valine
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247142A
Other languages
English (en)
French (fr)
Inventor
Philip Janiak
Marie-Laure Ozoux
Daniela ROVERSI
Elisabetta Bianchi
Martina TRIPEPI
Alessia Santoprete
Original Assignee
Corteria Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corteria Pharmaceuticals filed Critical Corteria Pharmaceuticals
Publication of CA3247142A1 publication Critical patent/CA3247142A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
CA3247142A 2022-02-23 2023-02-21 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY Pending CA3247142A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
EP22158188.7 2022-02-23
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
CA3247142A1 true CA3247142A1 (en) 2023-08-31

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247142A Pending CA3247142A1 (en) 2022-02-23 2023-02-21 CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY

Country Status (15)

Country Link
US (1) US20260001928A1 (https=)
EP (2) EP4234574A1 (https=)
JP (1) JP2025508820A (https=)
KR (1) KR20240153565A (https=)
CN (1) CN118843638A (https=)
AU (1) AU2023224327A1 (https=)
CA (1) CA3247142A1 (https=)
ES (1) ES3063881T3 (https=)
HR (1) HRP20260115T1 (https=)
IL (1) IL314055A (https=)
IS (1) IS050770A (https=)
MX (1) MX2024010296A (https=)
PL (1) PL4482578T3 (https=)
WO (1) WO2023161229A1 (https=)
ZA (1) ZA202406196B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104264A1 (en) * 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US20250243255A1 (en) * 2020-08-19 2025-07-31 Sanofi Crf2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
KR20240153565A (ko) 2024-10-23
IS050770A (is) 2024-10-15
CN118843638A (zh) 2024-10-25
ZA202406196B (en) 2025-03-26
EP4482578C0 (en) 2025-12-24
ES3063881T3 (en) 2026-04-21
EP4482578B1 (en) 2025-12-24
EP4482578A1 (en) 2025-01-01
IL314055A (en) 2024-09-01
HRP20260115T1 (hr) 2026-03-13
EP4234574A1 (en) 2023-08-30
JP2025508820A (ja) 2025-04-10
MX2024010296A (es) 2024-09-18
US20260001928A1 (en) 2026-01-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
PL4482578T3 (pl) 2026-03-16

Similar Documents

Publication Publication Date Title
CN111491658B (zh) 肠促胰岛素类似物及其用途
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
EP4199946B1 (en) Crf2 receptor agonists and their use in therapy
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
EP2036923A1 (en) Improved derivates of amylin
AU2024215381A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
HK40095414A (en) Crf2 receptor agonists and their use in therapy
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
HK40029618B (en) Incretin analogs and uses thereof

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240705

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241213

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241213

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241213

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250108

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20250108